Электронная медицинская библиотека Румедо.

Зарубежные материалы

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Дата публикации 19.11.2020
Bernard Zinman, M.D., Christoph Wanner, M.D., John M. Lachin, Sc.D., David Fitchett, M.D., Erich Bluhmki, Ph.D., Stefan Hantel, Ph.D., Michaela Mattheus, Dipl. Biomath., Theresa Devins, Dr.P.H., Odd Erik Johansen, M.D., Ph.D., Hans J. Woerle, M.D., Uli C. Broedl, M.D., and Silvio E. Inzucchi, M.D., for the EMPA-REG OUTCOME Investigators
N Engl J Med 2015;373:2117-28. DOI: 10.1056/NEJMoa1504720

The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

Подробнее

615

Зарубежные материалы

Obesity. preventing and managing the global epidemic. 1997, Geneva. WHO. p. 159-276

Дата публикации 19.11.2020
World Health Organization

WHO Consultation on Obesity (‎1997: Geneva, Switzerland)‎, World Health Organization. Division of Noncommunicable Diseases & World Health Organization. Programme of Nutrition, Family and Reproductive Health. (‎1998)‎. Obesity : preventing and managing the global epidemic : report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. World Health Organization.

Подробнее

493

Зарубежные материалы

Obesity : preventing and managing the global epidemic : report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997

Дата публикации 19.11.2020
World Health Organization
WHO/NUT/NCD/98.1

WHO Consultation on Obesity (‎1997: Geneva, Switzerland)‎, World Health Organization. Division of Noncommunicable Diseases & World Health Organization. Programme of Nutrition, Family and Reproductive Health. (‎1998)‎. Obesity : preventing and managing the global epidemic : report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. World Health Organization.

Подробнее

486

Зарубежные материалы

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

Дата публикации 19.11.2020
E.A. Bohula, S.D. Wiviott, D.K. McGuire, S.E. Inzucchi, J. Kuder, K.A. Im, C.L. Fanola, A. Qamar, C. Brown, A. Budaj, A. Garcia‑Castillo, M. Gupta, L.A. Leiter, N.J. Weissman, H.D. White, T. Patel, B. Francis, W. Miao, C. Perdomo, S. Dhadda, M.P. Bonaca, C.T. Ruff, A.C. Keech, S.R. Smith, M.S. Sabatine, and B.M. Scirica, for the CAMELLIA–TIMI 61 Steering Committee and Investigators
N Engl J Med 2018;379:1107-17. DOI: 10.1056/NEJMoa1808721

Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined.

Подробнее

550

Зарубежные материалы

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Дата публикации 19.11.2020
S.D. Wiviott, I. Raz, M.P. Bonaca, O. Mosenzon, E.T. Kato, A. Cahn, M.G. Silverman, T.A. Zelniker, J.F. Kuder, S.A. Murphy, D.L. Bhatt, L.A. Leiter, D.K. McGuire, J.P.H. Wilding, C.T. Ruff, I.A.M. Gause‑Nilsson, M. Fredriksson, P.A. Johansson, A.-M. Langkilde, and M.S. Sabatine, for the DECLARE–TIMI 58 Investigators
N Engl J Med 2019;380:347-57. DOI: 10.1056/NEJMoa1812389

The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium – glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.

Подробнее

544

Зарубежные материалы

2018 ESC/ESH Guidelines for the management of arterial hypertension

Дата публикации 19.11.2020
Bryan Williams* (ESC Chairperson) (UK), Giuseppe Mancia* (ESH Chairperson) (Italy), Wilko Spiering (The Netherlands), Enrico Agabiti Rosei (Italy), Michel Azizi (France), Michel Burnier (Switzerland), Denis L. Clement (Belgium), Antonio Coca (Spain), Giovanni de Simone (Italy), Anna Dominiczak (UK), Thomas Kahan (Sweden), Felix Mahfoud (Germany), Josep Redon (Spain), Luis Ruilope (Spain), Alberto Zanchetti† (Italy), Mary Kerins (Ireland), Sverre E. Kjeldsen (Norway), Reinhold Kreutz (Germany), Stephane Laurent (France), Gregory Y. H. Lip (UK), Richard McManus (UK), Krzysztof Narkiewicz (Poland), Frank Ruschitzka (Switzerland), Roland E. Schmieder (Germany), Evgeny Shlyakhto (Russia), Costas Tsioufis (Greece), Victor Aboyans (France), and Ileana Desormais (France)
European Heart Journal (2018) 39, 3021–3104 doi:10.1093/eurheartj/ehy339

Подробнее

540

Зарубежные материалы

The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes

Дата публикации 19.11.2020
Victor J. Dzau, MD; Elliott M. Antman, MD; Henry R. Black, MD; David L. Hayes, MD; JoAnn E. Manson, MD, DrPH; Jorge Plutzky, MD; Jeffrey J. Popma, MD; William Stevenson, MD
DOI: 10.1161/CIRCULATIONAHA.106.655688

Fifteen years ago, a panel of experts representing the full spectrum of cardiovascular disease (CVD) research and practice assembled at a workshop to examine the state of knowledge about CVD. The leaders of the workshop generated a hypothesis that framed CVD as a chain of events, initiated by a myriad of related and unrelated risk factors and progressing through numerous physiological pathways and ...

Подробнее

420

Зарубежные материалы

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death

Дата публикации 19.11.2020
The New England Journal of Medicine
nejm.org on October 23, 2020.

The extent to which diabetes mellitus or hyperglycemia is related to risk of death from cancer or other nonvascular conditions is uncertain.

Подробнее

489

Зарубежные материалы

The effects of postnatal health education for mothers on infant care and family planning practices in Nepal: a randomised controlled trial

Дата публикации 19.11.2020
Alison Bolam, Dharma S Manandhar, Purna Shrestha, Matthew Ellis, Anthony M de L Costello
BMJ VOLUME 316 14 MARCH 1998

Mothers in groups A and B (received health education at birth) were slightly more likely to use contraception at six months after birth compared with mothers in groups C and D (no health education at birth) (odds ratio 1.62, 95% confidence interval 1.06 to 2.5). There were no other significant differences between groups with regards to infant feeding, infant care, or immunisation.

Подробнее

410

Статьи

Сахарный диабет 2-го типа и хроническая сердечная недостаточность – «Несладкая парочка»

Дата публикации 19.11.2020
И.Г. Починка, ФГБОУ ВО «Нижегородская государственная медицинская академия»
№ 6 (51) ноябрь 2017 МЕДИЦИНСКИЙ АЛЬМАНАХ

Подробнее

449

Зарубежные материалы

Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study

Дата публикации 19.11.2020
Frederik Persson MD, DMSc, Thomas Nyström MD PhD, Marit E. Jørgensen MD PhD, Bendix Carstensen MSc, Hanne L. Gulseth MD PhD, Marcus Thuresson PhD, Peter Fenici MD PhD, David Nathanson MD PhD, Jan W. Eriksson MD PhD, Anna Norhammar MD PhD, Johan Bodegard MD PhD, Kåre I. Birkeland MD PhD
DOI: 10.1111/dom.13077

After matching, a total of 40 908 patients with T2D were identified as new users of dapagliflozin (n = 10 227) or a DPP-4 inhibitor (n = 30 681). The groups were well balanced at baseline; their mean age was 61 years and 23% had CV disease. The mean follow-up time was 0.95 years, with a total of 38 760 patient-years. Dapagliflozin was associated with a lower risk of MACE, HHF and all-cause mortal ...

Подробнее

572

Зарубежные материалы

Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes

Дата публикации 19.11.2020
Peter Gæde, M.D., D.M.Sc., Henrik Lund-Andersen, M.D., D.M.Sc., Hans-Henrik Parving, M.D., D.M.Sc., and Oluf Pedersen, M.D., D.M.Sc.
N Engl J Med 2008;358:580-91.

Intensified multifactorial intervention — with tight glucose regulation and the use of renin–angiotensin system blockers, aspirin, and lipid-lowering agents — has been shown to reduce the risk of nonfatal cardiovascular disease among patients with type 2 diabetes mellitus and microalbuminuria. We evaluated whether this approach would have an effect on the rates of death from any cause and from ca ...

Подробнее

453

Зарубежные материалы

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Дата публикации 19.11.2020
Eri T. Kato, MD, MPH, PhD et al
Circulation. 2019;139:2528–2536. DOI: 10.1161/CIRCULATIONAHA.119.040130

In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) ...

Подробнее

493

Зарубежные материалы

Pioglitazone Initiation and Subsequent Hospitalisation for Congestive Heart Failure

Дата публикации 19.11.2020
Andrew J. Karter, Ph.D., Ameena T. Ahmed, M.D., M.P.H., Jennifer Liu, M.P.H., Howard H. Moffet, M.P.H., and Melissa M. Parker, M.S.
Diabet Med. 2005 August ; 22(8): 986–993. doi:10.1111/j.1464-5491.2005.01704.x.

Thiazolidinediones (TZD) have been associated with an expansion in plasma volume and the development of peripheral oedema. A recent study reported an association between the use of TZDs and development of congestive heart failure (CHF). The objective of this study was todetermine if short-term use of pioglitazone, a TZD, is associated with increased risk of CHF hospitalisation in a well-character ...

Подробнее

482

Зарубежные материалы

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial

Дата публикации 19.11.2020
Anders Jorsal, Caroline Kistorp, Pernille Holmager, Rasmus Stilling Tougaard, Roni Nielsen, Anja Hänselmann, Brian Nilsson, Jacob Eifer Møller, Jakob Hjort, Jon Rasmussen, Trine Welløv Boesgaard, Morten Schou, Lars Videbæk, Ida Gustafsson, Allan Flyvbjerg, Henrik Wiggers, Lise Tarnow
European Journal of Heart Failure (2017) 19, 69–77 doi:10.1002/ejhf.657

In patients with chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF), angiotensin-converting enzyme inhibitors, beta-blockers, and spironolactone reduce mortality and improve LVEF. However, long-term survival and quality of life remain markedly impaired, especially in patients with diabetes. We therefore need new, safe treatment modalities that can improve CHF symptom ...

Подробнее

510

БИБЛИОТЕКА